In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon
- PMID: 3114409
- PMCID: PMC2188698
- DOI: 10.1084/jem.166.3.798
In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon
Abstract
The (NZB X NZW)F1 mouse is recognized as an important animal model of the human disease systemic lupus erythematosus (SLE). Groups of NZB/W F1 mice were treated either with IFN-gamma or with PBS. The results demonstrate that IFN-treated animals have accelerated development of fatal immune complex glomerulonephritis relative to age-matched controls. On the other hand, administration of mAbs specific for IFN-gamma to such mice from 4 to 7 mo of age resulted in significant remission. Development of both proteinuria and anti-DNA antibodies were delayed and survival at 11 mo was increased from less than 20% to 95% in treated mice relative to controls (p less than or equal to 0.001). These findings may have therapeutic implications for the treatment of SLE.
Similar articles
-
Animal models utilized in the research of autoimmune disease control: experimental therapy of glomerulonephritis in NZB/W F1 mice.Prog Clin Biol Res. 1987;229:157-74. Prog Clin Biol Res. 1987. PMID: 3601985
-
CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.Arthritis Rheum. 2012 Apr;64(4):1237-46. doi: 10.1002/art.33424. Epub 2011 Oct 17. Arthritis Rheum. 2012. PMID: 22006377
-
Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).Ann Rheum Dis. 2008 Feb;67(2):154-61. doi: 10.1136/ard.2006.068981. Epub 2007 Jun 8. Ann Rheum Dis. 2008. PMID: 17557887
-
Origins of pathogenic anti-DNA idiotypes in the NZB X SWR model of lupus nephritis.Ann N Y Acad Sci. 1986;475:47-58. doi: 10.1111/j.1749-6632.1986.tb20855.x. Ann N Y Acad Sci. 1986. PMID: 2947530 Review.
-
Nuclease deficiencies promote end-stage lupus nephritis but not nephritogenic autoimmunity in (NZB × NZW) F1 mice.Immunol Cell Biol. 2011 Jan;89(1):90-9. doi: 10.1038/icb.2010.75. Epub 2010 Jun 15. Immunol Cell Biol. 2011. PMID: 20548325 Review.
Cited by
-
Th1/17 polarization and potential treatment by an anti-interferon-γ DNA aptamer in Hunner-type interstitial cystitis.iScience. 2023 Oct 21;26(11):108262. doi: 10.1016/j.isci.2023.108262. eCollection 2023 Nov 17. iScience. 2023. PMID: 38026177 Free PMC article.
-
Systemic Inflammatory Disorders, Immunosuppressive Treatment and Increase Risk of Head and Neck Cancers-A Narrative Review of Potential Physiopathological and Biological Mechanisms.Cells. 2023 Sep 1;12(17):2192. doi: 10.3390/cells12172192. Cells. 2023. PMID: 37681925 Free PMC article. Review.
-
IFN-γ and TGF-β, Crucial Players in Immune Responses: A Tribute to Howard Young.J Interferon Cytokine Res. 2022 Dec;42(12):643-654. doi: 10.1089/jir.2022.0132. J Interferon Cytokine Res. 2022. PMID: 36516375 Free PMC article. Review.
-
IFN-γ, should not be ignored in SLE.Front Immunol. 2022 Aug 10;13:954706. doi: 10.3389/fimmu.2022.954706. eCollection 2022. Front Immunol. 2022. PMID: 36032079 Free PMC article. Review.
-
Immunomodulatory Activity of Mesenchymal Stem Cells in Lupus Nephritis: Advances and Applications.Front Immunol. 2022 Mar 10;13:843192. doi: 10.3389/fimmu.2022.843192. eCollection 2022. Front Immunol. 2022. PMID: 35359961 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical